Beyond Air, Inc. (XAIR): Price and Financial Metrics


Beyond Air, Inc. (XAIR): $6.49

-0.53 (-7.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

XAIR POWR Grades


  • Sentiment is the dimension where XAIR ranks best; there it ranks ahead of 79.44% of US stocks.
  • The strongest trend for XAIR is in Momentum, which has been heading down over the past 179 days.
  • XAIR's current lowest rank is in the Value metric (where it is better than 5.77% of US stocks).

XAIR Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for XAIR is 0 -- better than merely 6.09% of US stocks.
  • XAIR's price/sales ratio is 1,421.64; that's higher than the P/S ratio of 99.69% of US stocks.
  • Revenue growth over the past 12 months for Beyond Air Inc comes in at -72.53%, a number that bests only 1.77% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Beyond Air Inc, a group of peers worth examining would be SPCE, VBIV, GH, NVCR, and BFLY.
  • XAIR's SEC filings can be seen here. And to visit Beyond Air Inc's official web site, go to www.beyondair.net.

XAIR Valuation Summary

  • In comparison to the median Healthcare stock, XAIR's price/sales ratio is 10663.16% higher, now standing at 409.
  • Over the past 28 months, XAIR's price/sales ratio has gone NA NA.
  • Over the past 28 months, XAIR's price/earnings ratio has gone down 4.8.

Below are key valuation metrics over time for XAIR.

Stock Date P/S P/B P/E EV/EBIT
XAIR 2021-08-31 409.0 7.9 -11.5 -10.4
XAIR 2021-08-30 419.9 8.1 -11.8 -10.7
XAIR 2021-08-27 423.6 8.2 -11.9 -10.8
XAIR 2021-08-26 406.1 7.8 -11.4 -10.3
XAIR 2021-08-25 383.1 7.4 -10.8 -9.6
XAIR 2021-08-24 354.8 6.8 -10.0 -8.8

XAIR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XAIR has a Quality Grade of D, ranking ahead of 10.23% of graded US stocks.
  • XAIR's asset turnover comes in at 0.019 -- ranking 165th of 186 Medical Equipment stocks.
  • ANGO, CLPT, and EW are the stocks whose asset turnover ratios are most correlated with XAIR.

The table below shows XAIR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.019 1 -4.212
2021-03-31 0.030 1 -5.011
2020-12-31 0.020 1 -7.880
2020-09-30 0.029 1 -5.011
2020-06-30 0.048 1 -4.730
2020-03-31 0.081 1 -3.709

XAIR Price Target

For more insight on analysts targets of XAIR, see our XAIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.3 (Strong Buy)

XAIR Stock Price Chart Interactive Chart >

Price chart for XAIR

XAIR Price/Volume Stats

Current price $6.49 52-week high $16.41
Prev. close $7.02 52-week low $4.78
Day low $6.47 Volume 446,000
Day high $7.02 Avg. volume 256,267
50-day MA $5.94 Dividend yield N/A
200-day MA $8.52 Market Cap 193.60M

Beyond Air, Inc. (XAIR) Company Bio


Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.


XAIR Latest News Stream


Event/Time News Detail
Loading, please wait...

XAIR Latest Social Stream


Loading social stream, please wait...

View Full XAIR Social Stream

Latest XAIR News From Around the Web

Below are the latest news stories about Beyond Air Inc that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Beyond Air (NASDAQ:XAIR) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 22, 2022

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer™, Beyond Air maintained an 80% equity ownership; first in human trial initiation on track for first half of calendar year 2022 Expansion of leadership team with appointment of Dr. Andrew Colin to Chief Medical Officer tasked with leading the strategic

Yahoo | February 10, 2022

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive

Yahoo | February 8, 2022

Beyond Air® Announces Two Appointments to Beyond Cancer Board of Directors

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

Benzinga | February 3, 2022

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company

Yahoo | February 3, 2022

Read More 'XAIR' Stories Here

XAIR Price Returns

1-mo 14.06%
3-mo -3.13%
6-mo -31.32%
1-year -9.23%
3-year 25.78%
5-year N/A
YTD -31.25%
2021 79.13%
2020 0.76%
2019 12.47%
2018 -6.81%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4361 seconds.